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High-affinity interactions and signal transduction
between Ab oligomers and TREM2
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Thomas E Mahan3, Paramita Chakrabaty1,4, David M Holtzman3 , Jason D Ulrich3, Marco Colonna2 &
Todd E Golde1,4,*
Abstract
Rare coding variants in the triggering receptor expressed on
myeloid cells 2 (TREM2) are associated with increased risk for
Alzheimer’s disease (AD), but how they confer this risk remains
uncertain. We assessed binding of TREM2, AD-associated TREM2
variants to various forms of Ab and APOE in multiple assays. TREM2
interacts directly with various forms of Ab, with highest affinity
interactions observed between TREM2 and soluble Ab42 oligomers.
High-affinity binding of TREM2 to Ab oligomers is characterized by
very slow dissociation. Pre-incubation with Ab is shown to block
the interaction of APOE. In cellular assays, AD-associated variants
of TREM2 reduced the amount of Ab42 internalized, and in NFAT
assay, the R47H and R62H variants decreased NFAT signaling activ-
ity in response to Ab42. These studies demonstrate i) a high-affi-
nity interaction between TREM2 and Ab oligomers that can block
interaction with another TREM2 ligand and ii) that AD-associated
TREM2 variants bind Ab with equivalent affinity but show loss of
function in terms of signaling and Ab internalization.
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Introduction
The most prevalent form of dementia, Alzheimer’s disease (AD), is
hypothesized to be triggered by accumulation of aggregated
amyloid-b (Ab) followed by a “cascade-like” chain of events that
includes induction of tauopathy, neurodegeneration, and alterations
in innate immune signaling (Hardy & Selkoe, 2002; Musiek &
Holtzman, 2015). The later feature is reflected by the presence of
a reactive astrocytosis, microgliosis, and increased level and accu-
mulation of a variety of immune molecules. A more central role of
the innate immune system and microglial cells in particular has
emerged from genetic studies. These studies show that numerous
loci encoding immune genes are associated with altered risk for AD.
Even more compelling are data showing that coding variants in
three different genes (TREM2, PLCG2, and ABI3), whose transcripts
are expressed primarily in microglial cells in the brain, alter risk for
AD (Golde et al, 2013; Jin et al, 2014; Sims et al, 2017). Despite these
associations between the immune system and AD, there is little
consensus as to how alterations in the immune system mechanisti-
cally alter AD risk. Modeling studies reveal a complex relationship
between immune activation states, the proteinopathies found in AD,
and neurodegeneration—a phenomenon we refer to as immunopro-
teostasis (Chakrabarty et al, 2015). Further, definitive insight into
how genetic variations within immune loci that alter AD risk alter
immune function has remained enigmatic. Further understanding of
how genetic risk factors impact the immune function will be impor-
tant to guide therapeutic development, that to date has largely
focused on anti-inflammatory strategies (Chakrabarty et al, 2015).
The rare protein coding variants in TREM2, R47H, and R62H,
which are reproducibly associated with increased risk for develop-
ing AD, are being intensively studied as these variants were the first
coding variants in an innate immune gene that have been repro-
ducibly shown to alter risk for AD (Cruchaga et al, 2013; Jin et al,
2015; Lill et al, 2015). Prior to association with AD, homozygous or
compound heterozygous mutations in TREM2 had been identified in
a disease called polycystic lipomembranous osteodysplasia with
sclerosing leukoencephalopathy (PLOSL) or Nasu-Hakola disease
(Bianchin et al, 2006). PLOSL is characterized by fractures, frontal
lobe syndrome, and progressive presenile dementia beginning in the
fourth decade. Numerous studies of the PLOSL-associated TREM2
variants suggest that these variants are loss of function altering
maturation and cell-surface expression of TREM2 (Paloneva et al,
2001, 2002). Both structural and cell biology studies of the AD
TREM2 variants show they lie on the surface of the TREM2 ectodo-
main, possibly framing a binding pocket, whereas the PLOSL
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variants are within the core structure (Kleinberger et al, 2014; Kober
et al, 2016). Maturation studies demonstrate folding and maturation
deficits induced by PLOSL-associated TREM2 variants, whereas the
AD variants do not consistently show these same functional impair-
ments. Notably, a DNA polymorphism within a DNase hypersensi-
tive site 50 of TREM2, rs9357347-C, also associates with reduced AD
risk and increased TREML1 and TREM2 levels (Carrasquillo et al,
2017). This variant is associated with decreased risk for AD, which
would be consistent with the hypothesis that the coding variants in
TREM2 associated with increased AD risk are partial loss of
function.
TREM2 is a type I transmembrane glycoprotein that interacts
with the transmembrane region of DAP12 (TYROBP) to mediate
signaling events through DAP12’s immunoreceptor tyrosine-based
activation motif (ITAM) domain (Peng et al, 2010). The extracel-
lular, immunoglobulin-like domain V type, domain of TREM2 is
glycosylated and shows cell-surface localization. TREM2 is highly
expressed in microglia and peripheral macrophages (Colonna &
Wang, 2016). TREM2 is one member of a family of receptors that
have diverged between mouse and humans. In both mouse and
human, the family members are clustered within a single chromo-
somal region on chromosome 6. In the context of neurodegenera-
tive disease, the other family members have not been intensively
studied as they are typically expressed at much lower levels in
the brain. Like many type I membrane receptors, TREM2 can
undergo ectodomain shedding and subsequent intramembrane
cleavage by c-secretase (Wunderlich et al, 2013). The physiologic
implications of these proteolytic cleavages remain unclear, though
increased soluble TREM2 has been reported in the CSF of early-
stage Alzheimer’s disease (Suarez-Calvet et al, 2016), and study
of a variant p.H157Y reported to be associated with AD in the
Han Chinese population has been shown to increase ectodomain
shedding (Jiang et al, 2016a; Schlepckow et al, 2017; Thornton
et al, 2017). Enhanced shedding activity from the mutation
p.H157Y located in the ectodomain cleavage site leads to a
reduced cell-surface TREM2 and phagocytic activity (Schlepckow
et al, 2017; Thornton et al, 2017).
TREM2 has been implicated in multiple functions including
migration, survival and proliferation, cytokine release, and phagocy-
tosis (Kleinberger et al, 2014; Ulrich & Holtzman, 2016; Yuan et al,
2016). TREM2 appears to be a promiscuous receptor and has been
shown to interact with cellular debris, bacteria, anionic phospho-
lipids, nucleic acids, and apolipoprotein E (APOE; Atagi et al, 2015;
Bailey et al, 2015; Yeh et al, 2016; Kober & Brett, 2017; Song et al,
2017). Alterations in signaling and binding of TREM2 AD variants
compared to wild-type (WT) TREM2 have been reported, though
the pathogenic relevance of these alterations is not yet completely
clear (Kleinberger et al, 2014; Kober et al, 2016). Mouse modeling
studies show increased TREM2 expression in multiple models of
neurodegenerative diseases, and TREM2-positive microglial cells
appear to surround plaques in APP models (Jiang et al, 2014; Ulrich
et al, 2014; Yuan et al, 2016; Jay et al, 2017). TREM2 also shows an
altered distribution in microglia surrounding the amyloid plaque,
with much of the TREM2 immunoreactivity localized within the
plasma membrane of the microglial cells adjacent to the plaque. In
TREM2 knockout mice crossed with APP, there are fewer microglial
cells surrounding plaques and an increase in plaques with “specu-
lar” amyloid morphology as well as more neuritic dystrophy (Wang
et al, 2015, 2016). Such data have led to the hypothesis that TREM2
may regulate the interaction of microglia with plaques and protect
other brain cells from toxicity.
In this study, we investigated whether TREM2 and its AD vari-
ants interact directly with Ab. We found no significant changes in
the binding affinity between Ab42 with TREM2 or the AD variants
or with their mouse counterpart Trem2, Trem1, and Treml1. Despite
this lack of difference in the binding affinity, we observed an attenu-
ated activation of NFAT signaling and a reduced amount of Ab42
internalized by cells expressing the TREM2 AD variants. We show
that TREM2, TREM1 and TREML1 bind APOE and Ab variably. Our
study reveals that the TREM2 and other family members can bind
various forms of Ab and that Ab oligomers can induce singling
events. Further, our data are consistent with the hypothesis that AD
risk variants in TREM2 induce a partial loss of function (Song et al,
2018), but do not directly alter binding affinity for either Ab or
APOE.
Results
Soluble TREM2-Fc and soluble TREML1-Fc interact with
Ab42 fibrils
The ectodomain of TREM2 interacts with various ligands including
bacterial liposaccharides and phospholipids. We explored whether
TREM2 might interact with Ab and whether this interaction might
be affected by the AD variants. We also analyzed mouse Trem2 in
order to compare its relative binding ability to human TREM2.
Initial studies focused on whether TREM2 could interact with fibril-
lar Ab42 (fAb), using an Ab42 pull-down assay we have previously
validated (Chakrabarty et al, 2015). Conditioned media from transi-
ently transfected HEK 293 cells expressing the soluble ectodomains
of (i) human TREM2 fused to the Fc domain of human IgG4
(sTREM2-Fc), (ii) AD-associated TREM2 variants (sTREM2-R47HFc,
sTREM2-R62H), (iii) mouse TREM2 (sTrem2-FC) or (iv) Fc control
was incubated with fAb. These were spun at 18,000 g to pellet fAb
associated proteins. sTREM2, sTREM2-R47H and sTREM2-R62H
were enriched in the fAb pellet (Figs 1A and EV1A), whereas the Fc
control was not detected in the pellet. Mouse sTrem2 also showed
binding to Ab fibrils. Similar pull-down assay between fAb and full-
length TREM2 was conducted using the cleared RIPA lysate from
TREM2, TREM2-R47H, and TREM2-R62H transiently transfected
into HEK293T cells. Although less efficient, presumably because of
detergent present in the lysate, full-length TREM2 and the AD vari-
ants were pulled down by fAb (Figs 1B and EV1B).
Multiple studies show TREM2 ectodomain interacts with APOE
(Atagi et al, 2015; Bailey et al, 2015; Yeh et al, 2016). To confirm
that the sTREM2-Fc proteins are functional and bind APOE3, we co-
transfected TREM2-Fc constructs with APOE3 and pulled down
proteins that bound sTREM2-Fc with anti-IgG Fc agarose beads.
These data show that the TREM2 ectodomain binds APOE and that
there is no major difference in binding between the AD variants and
WT TREM2 (Figs 1C and EV1C). In this experiment, a minor inter-
action between the human sIgG4-Fc domain and APOE3 is
observed.
TREM2 is a member of a multiprotein family that is divergent
between human and mice. We explored whether select members of
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the TREM2 family bind Ab42 fibrils and APOE. We repeated the fAb
pull-down experiments in Fig 1A with two other soluble family
members, which share low sequence homology with each and
other: TREM1-Fc and TREML1-Fc. In Fig 1D, we confirm presence
of soluble TREM2-Fc and TREML1-Fc in the pelleted Ab42 fibrils.
Soluble TREM1-Fc was not detected in the pelleted fAb. Soluble
A B
C D E
Figure 1. Soluble TREM2 and soluble TREML1-Fc bind Ab42 fibrils.
A Media from soluble TREM2-Fc transfected HEK293T cells incubated with Ab42 fibrils. Top left panel shows original media samples. Top right panel shows the
presence of soluble TREM2 associated with Ab42 pellet. The bottom two panels represent the same samples as the top, but probed with 6E10.
B RIPA lysate from TREM2 transfected HEK293T cells incubated with Ab42 fibrils. Top left panel shows original RIPA lysate samples, and top right panel shows the
presence of TREM2 associated with Ab42 pellet. The bottom two panels represent the same samples as the top, but probed with 6E10.
C Media from soluble TREM2-Fc and APOE3 co-transfected HEK293T cells incubated with agarose beads anti-human IgG Fc. Left panels show original media samples.
Right panels show the purified soluble TREM2-Fc (bottom) and the presence of APOE3 with the purified soluble TREM2-Fc (top).
D Media from soluble TREM-Fc family member transfected HEK293T cells incubated with Ab42 fibrils. Top panel shows original media sample and the presence of
TREM family members associated with Ab42 pellet. Bottom panel shows original media and Ab42 pellet probed with 6E10.
E Media from soluble TREM-Fc family members and APOE3 co-transfected HEK293T cells incubated with agarose beads anti-human IgG Fc. Top panel shows original
media sample and the presence of soluble TREM family members associated with APOE3. Bottom panel shows original media and purified soluble TREM-Fc family
members probed with anti-V5.
Data information: All experiments were replicated 3 independent times. Western blots in panels (A, B and C) have been cropped. The originals showing the supernatant
fractions are available as Fig EV1.
Source data are available online for this figure.
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TREM1-Fc like soluble TREM2-Fc interacts with APOE3, but there is
lack of detectable interaction between soluble TREML1-Fc and
APOE3 (Fig 1E).
Soluble TREM2-Fc and AD variants interact with Ab monomers
or APOE with a similar affinity, and soluble TREM-Fc family
members interact with Ab42 oligomers with a higher affinity
We used BioLayer Interferometry (BLI) to further explore the inter-
action between Ab and TREM2 and other TREM family members.
By immobilizing the TREM proteins on the BLI sensor, ligand
interaction can be monitored in real time, enabling precise deter-
mination of the association and dissociation constants. As poorly
soluble fAb does not produce detectable binding in this assay even
with high-affinity control anti-Ab antibodies, we were only able to
assess binding with Ab42 oligomers and Ab40 and Ab42 mono-
mers. We initially explored interactions between Ab42 oligomers
and sTREM2-Fc in the BLI assay. These data revealed that
sTREM2 bound Ab42 oligomers with high affinity largely attribu-
table to a very slow dissociation. In these initial studies, we also
found no interaction between the Fc alone and Ab42 oligomers.
Further, when a high-affinity anti-Ab1-16 antibody (Ab5) was
incubated following the dissociation step, we were able to demon-
strate that the Ab oligomers were indeed tightly complexed with
sTREM2 on the sensor (Fig EV2A). After further optimization of
the assay (see methods), we systematically evaluated the binding
of sTREM-Fc proteins to various concentrations of Ab42 oligomers,
Ab42 monomers Ab40 monomers, as well as lipidated recombi-
nant APOE3 and APOE4 (Figs 2A and B, and EV2B). Under these
optimized conditions, no sFc binding is observed, and non-specific
binding of APOE3 or APOE4 eliminated. These studies enabled
precise determination of the Kon, Kdis (Koff), and the overall KD
(Fig 2C) of various form of Ab and APOE under identical condi-
tions. These studies revealed very high-affinity binding between
Ab42 oligomers and sTREM2-Fc and the AD variants (<1.0 E-
12 M). This strong binding is largely attributable to the apparent
irreversibility of the binding. Indeed, the dissociation constants are
the maximal measurable (Kdis = 1.0 E-07 1/s) on the Octet Red
instrument. In contrast to the binding observed between sTREM2
and Ab42 oligomers, binding to Ab42 monomers was much
weaker and reversible (KD from 1.4 to 2.9 E-07 M). The KDs of
the WT TREM2 were not statistically different from the AD vari-
ants. Binding to Ab40 monomers was similar to binding to Ab42
monomers (KDs from 1.4 to 2.7 E-07 M), and again, the KDs of
the WT TREM2 were not statistically different from the AD vari-
ants. We also established KDs in the nm range for binding of lipi-
dated APOE3 and APOE4 with sTREM2. KDs for APOE3 binding
sTREM2 or the AD variants were very similar and not statistically
different. Binding of APOE4 revealed a slight increase in binding
affinity of R47H variant (1.7 fold) and the R62H variant (1.56-fold)
with APOE4 that was statistically significant. Given the irreversible
nature of the Ab42 oligomers binding to sTREM2, we explored
whether the binding of Ab42 oligomers could block interaction
with APOE3. We evaluated whether pre-incubation with Ab42
oligomers to sTREM2 could block subsequent interaction with
APOE3. As shown in Fig 3, binding of Ab42 oligomers blocked
APOE3 binding. In contrast, addition of Ab42 oligomers to
sTREM2 previously bound to APOE3 did not block subsequent
interaction with Ab42 oligomers. We next examined the binding of
select soluble mouse and human TREM family members with
Ab42 oligomers by BLI (Fig 2D). TREML1 showed a similar high-
affinity binding of Ab42 oligomers to TREM2 but the interaction
between TREM1 and Ab42 oligomers was much weaker (1.1E-
7 M). In contrast, both mouse Trem1 and Treml1 bound Ab42
oligomers with high affinity.
We further investigated the binding of fAb with soluble TREM2-
Fc and the AD variants by an ELISA binding assay due to their
unsuitability with BioLayer Interferometry. We compared the bind-
ing of fAb, Ab42 monomers, and Ab42 oligomers with soluble
TREM2-Fc and the AD variants. In Fig EV3, Ab42 fibrils incubated
with soluble TREM2-Fc and the AD variants or soluble Trem2-Fc
increased weakly the signal compared to the Fc control and showed
no significant differences. The Ab42 oligomers incubated with
soluble TREM2-Fc or the AD variants or soluble Trem2-FC
produced a signal significantly higher compared to Fc control and
around two times stronger than the one from the Ab42 monomers.
In Fig 4A, we tested Ab42 monomers at higher concentrations. A
significant signal between Fc control and the soluble TREM2-Fc or
the AD variants or soluble Trem2-Fc is obtained at 1,000 nM Ab42
monomers and more. This result confirms the binding of Ab42
monomers with soluble TREM2 and the AD variants and soluble
Trem2-Fc without significant differences between all of them. We
then repeated a similar ELISA assay with soluble TREM-Fc family
members and Ab42 oligomers. In Fig 4B, only soluble TREM2-Fc
and soluble TREML1-Fc produced a significant signal compared to
Fc control. This result confirms the binding of Ab42 oligomers with
soluble TREM2-Fc and soluble TREML1-Fc and lack of binding with
soluble TREM1-Fc.
Collectively, these biochemical experiments confirm a direct
interaction between Ab42 and TREM2 and the AD variants TREM2
R47H or TREM2 R62H and Trem2 without any significant dif-
ferences. Ab42 oligomers have a stronger affinity for TREM2 than
Ab42 monomers. TREML1 also binds Ab42 oligomers, but failed to
bind APOE3 contrary to TREM2 or TREM1.
Expression of TREM2 activates NFAT signaling and increases
internalized Ab42
We investigated whether the binding of Ab42 oligomers with
TREM2 activates cell signaling by exposing 2B4 NFAT-GFP reporter
cells transduced with TREM2 to various concentrations of Ab42
oligomers. As other TREM2 ligands activate NFAT in these cells, we
predicted that the high-affinity interaction with Ab42 oligomers
would also induce NFAT signaling. Control cells exposed to Ab42
oligomers weakly activated the GFP reporter compared to WT
TREM2 expressing cells (Fig 5A). Cells expressing TREM2 R47H and
exposed to Ab42 oligomers also activated the GFP reporter, but at
each concentration, the signal was lower than the signal in WT
TREM2 transduced cells. Further study of reporter cells expressing
WT TREM2, TREM2 R47H TREM2 R62H, or a putatively frontotem-
poral dementia (FTD) variant (TREM2 T96K) shows that the TREM2
AD variants R47H and R62H reduced NFAT activation whereas the
FTD variants TREM2 T96K activated NFAT signaling at similar level
then TREM2 (Fig 5B). These data demonstrate that TREM2 activates
NFAT signaling in presence Ab42 oligomers and this activation is
reduced by the AD variants TREM2 R47H or R62H.
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TREM2 expression in non-phagocytic cells confers phagocytic activ-
ity (Hsieh et al, 2009). To evaluate whether TREM2 expression induces
Ab42 uptake, we incubated Ab42 over HEK293T cells transiently trans-
fected with TREM2 and quantified internalized Ab42. Compared to
control transfection, TREM2 expression increased the amount of inter-
nalized Ab42 (Fig 5C). TREM2 R47H and R62H also increased internal-
ization levels relative to control, but the amount internalized was




Figure 2. Binding affinity of soluble TREM-Fc family members and AD variants with Ab42 oligomers, Ab42monomers, Ab40monomers, and APOE3 and APOE4.
BioLayer Interferometry experiments were performed to measure ligand binding affinity with soluble TREM-Fc family members and mouse soluble TREM-Fc family
members.
A Schematic representation of a full-length experiment.
B Schematic representation of Ab42 oligomers (right panel) and APOE4 (left panel) binding with soluble TREM2-Fc at various concentrations. Curves were fit by setting
buffer control (no ligand) to y = 0.
C Calculated Kon, Kdis, and KD values for Ab42 oligomers or Ab42 monomers, Ab40 monomers, or APOE3 or APOE4 association/dissociation with soluble TREM2-Fc and
AD variants. Kinetic constants were calculated using five different concentrations of ligand, and the entire experiment (including new ligand preparations and
purifications of soluble TREM-Fc) was repeated twice (#P < 0.05, ANOVA, Tukey’s multiple comparison test, see Appendix Table S1 for exact P-value).
D Calculated Kon, Kdis, and KD value for Ab42 oligomers association/dissociation with soluble human vs. mouse TREM-Fc family members. Kinetic constants were
calculated using five different concentrations of ligand, and the entire experiment (including new ligand preparations and purifications of soluble TREM-Fc) was
repeated twice.
Data information: Kon; constant of association, Kdis; constant of dissociation, KD; equilibrium constant of dissociation.
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We conducted several studies to further explore the reduced
uptake observed by the AD variants. First, we investigated whether
the shedding of TREM2 is affected by Ab. If Ab binding induces
shedding of the TREM2 ectodomain and the AD variants are shed
more, this could explain the decreased uptake observed. However,
as observed in Fig 5D, despite similar levels of membrane-
associated TREM2, TREM2 R47H, and TREM2 R62H, the amount of
soluble TREM2 was similar and not altered by oligomeric Ab. We
also rigorously evaluated cell-surface levels of TREM2 using cell-
surface biotinylation studies. These studies (Fig 5E) again revealed
no significant differences in levels as previously observed
(Kleinberger et al, 2014; Kober et al, 2016).
Discussion
We find that TREM2 binds to various forms of Ab with a very high-
affinity interaction with Ab42 oligomers. Further, TREM2 appears
capable of mediating Ab internalization and Ab oligomers induce
NFAT singling through TREM2. These data establish a direct link
between Ab aggregates, which are implicated as initiators of the
pathological cascade in AD and TREM2 a microglial immune recep-
tor. No difference in binding affinity between the AD-associated
variants and WT TREM2 to any form of Ab is detected. However,
AD-associated TREM2 variants appear to reduce both Ab internal-
ization and downstream NFAT signaling. Consistent with other
published data, these data indicate that TREM2 variants associated
with AD risk may act through subtle loss of function (Song et al,
2018). These data are also consistent with the reported protection
from AD attributable to a non-coding nucleotide polymorphism in
the TREM locus that increases both TREM2 and TREMl1 expression
(Carrasquillo et al, 2017). Indeed, a recent modeling study showed
that increased TREM2 levels reduced amyloid levels in an APP
mouse model and attenuated a number of other amyloid-associated
phenotypes in this model (Lee et al, 2018). As cell-surface levels of
the AD variants and WT TREM2 are similar in these studies and
there is no detectable difference in internalization or processing
either in the presence or absence of Ab, additional studies will be
needed to better understand the functional differences between the
AD variants and WT TREM2, which our data strongly suggest are
downstream of the initial binding event.
The differential binding affinities between various forms of Ab
and TREM2 are interesting. Binding to monomeric Ab is relatively
weak, whereas binding to oligomers is essentially irreversible.
Indeed, prior interaction of Ab oligomers blocks binding of a second
ligand, lipidated APOE. We have been unable to directly assess affi-
nities to fAb by BLI due to technical reasons, but do observe strong
interaction in the fAb pull-down assay in the absence of detergent.
In the presence of detergent or by ELISA, which also contains small
amount of detergent in the binding buffer, we observe a weaker
interaction. Collectively these data support a model in which vari-
ous forms of Ab interact with TREM2 with different affinity and that
difference in affinity appears to be attributable to conformational
differences.
Given (i) the polarized localization of TREM2 on the microglial
cells surrounding amyloid plaques (Jiang et al, 2014; Yuan et al,
2016; Jay et al, 2017) and (ii) the lack of homing of microglial to
plaques that is observed in knockout mouse models (Ulrich et al,
2014; Jay et al, 2015, 2017; Wang et al, 2015, 2016; Yuan et al,
2016), it is intriguing to consider that high-affinity interaction
Figure 3. Binding of Ab42 oligomers on soluble TREM-Fc prevents binding of APOE3 in BioLayer Interferometry.
BioLayer Interferometry experiments were performed to evaluate the binding capacity of APOE3 on soluble TREM2-Fc pre-incubated with Ab42 oligomers. Schematic
representations of two sequential associations of ligand on soluble TREM2-Fc are represented by I and II. Soluble TREM2-Fc loaded on a sensor is first incubated with
APOE3 (association I) followed by a second incubation with Ab42 oligomers (association II) or the reverse-incubated with Ab42 oligomers (association I) followed by a
second incubation with APOE3 (association II). All experiments were replicated 3 independent times.
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between Ab aggregates and TREM2 could underlie these observa-
tions. Although Ab oligomers are described as soluble, immunohis-
tochemical studies with select anti-oligomeric antibodies suggest
that Ab in an oligomeric conformation is present within plaques
(Koffie et al, 2009). This raises an interesting speculation that
TREM2 could interact with this plaque-associated oligomeric
conformer of Ab resulting in cell-surface polarization and microglial
homing (Tanzi, 2015; Yeh et al, 2017). Given the promiscuous
ligand specificity of TREM, and the apparent ability of Ab oligomers
to block subsequent ligand binding, it is hard to predict what the
biological effects of engagement of TREM2 by Ab oligomers would
be in the peri-plaque region. Depending on relative concentration of
ligands and relative efficiency of ligand-induced signaling the net
result could be either prolonged TREM2 activation or reduced
TREM2 activation.
Human TREM2 and mouse Trem2 are 68% identical and 76%
homologous, and they bind Ab oligomers with similar affinity.
These data would suggest that genetic manipulations of mouse
Trem2 are likely to be informative with respect to the interactions
with Ab. Although TREM2 is the most abundant TREM family
member based on expression levels in the brain, TREML1 is
present at appreciable levels (Carrasquillo et al, 2017). Further,
mouse Treml1 expression in the brain is dramatically increased
by the transgene inserted to knockout TREM2 in one of the
TREM2 mouse knockout models (Kang et al, 2018). Given that
Treml1 shows strong interaction with Ab oligomers, this could
contribute to the discrepancies reported in the various knockout
models with respect to effects on amyloid deposition. Our studies
of human TREM1 and TREML1 show that TREML1 binds Ab
oligomers with high affinity but TREM1 does not. Conversely,
TREM1 binds lipidated APOE but TREML1 does not. In contrast,
both mouse Treml1 and Trem1 bind Ab oligomers. These data
can provide a basis for understanding both the larger biological
role of TREM2 and family members in AD but also provide a
A
B
Figure 4. Binding of Ab42 monomers and Ab42 oligomers with soluble TREM2-Fc measured by ELISA assay.
ELISA plates were coated with purified soluble TREM2-Fc and then incubated with various concentrations of Ab42 monomers or 1 lM Ab42 oligomers.
A Binding of Ab42 monomers with soluble TREM2-Fc shows a dose-dependent signal. Results were expressed as the OD450 averaged  standard error (n = 3;
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, two-way ANOVA, Bonferroni multiple comparisons, see Appendix Table S2 for exact P-values).
B Binding of 1 lM Ab42 oligomers with soluble TREM-Fc family members. Results were expressed as the OD450 averaged  standard error (n = 4, *P < 0.05,
****P < 0.0001, ANOVA, Bonferroni multiple comparisons, see Appendix Table S2 for exact P-values).
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Figure 5. Ab42 oligomers induce TREM2 signaling and TREM2 mediates increased uptake of Ab42 in HEK cells.
A 2B4 NFAT-GFP reporter cells transduced with TREM2 or AD variant R47H were incubated with various concentrations of Ab42 oligomers for 12 h. GFP expression was
detected at 1 lM Ab42 oligomers with TREM2 transduced cells. No GFP expression was detected with Ab42 oligomers from control transduced cells. Results were
expressed as the percentage GFP cells averaged  standard error (n = 3, *P < 0.05 compared with mock, ****P < 0.0001 compared with mock, #P < 0.05 compared
with TREM2, ####P < 0.0001 compared with TREM2, two-way ANOVA, Bonferroni multiple comparisons, see Appendix Table S3 for exact P-values).
B B-2B4 NFAT-GFP reporter cells transduced with TREM2 or variants (R47H, R62H, and T96K) were incubated with 10 lM Ab42 oligomers for 12 h. No GFP expression
was detected with Ab42 oligomers from control transduced cells. Results were expressed as the percentage GFP cells averaged  standard error (n = 3, *P < 0.05
compared with TREM2, **P < 0.05 compared with TREM2, ****P < 0.0001 compared with TREM2, ##P < 0.01 compared with TREM2 T96K, ###P < 0.001 compared
with TREM2 T96K, ####P < 0.0001 compared with TREM2 T96K, ANOVA, Dunnett’s multiple comparisons test, see Appendix Table S3 for exact P-values.
C HEK293T cells transfected with TREM2 or AD variant incubated with 500 nM Ab42 monomers were lysed for Ab42 quantifications by ELISA. Expression of TREM2
increases Ab42 level detected compared to mock control as well the AD variant. Results were averaged  standard error (n = 9, #P < 0.05 compared with TREM2,
##P < 0.01 compared with TREM2, ***P < 0.001 compared with mock, ****P < 0.0001 compared with mock, ANOVA, Tukey’s multiple comparison test, see
Appendix Table S3 for exact P-values).
D HEK293T cells transfected with TREM2 were incubated with Ab42 oligomers for 16 h. Conditioned media and cell lysate were analyzed by Western blot for TREM2
(RIPA lysate) and soluble TREM2 (media) detection. Experiment was replicated 3 independent times.
E HEK293T cells transfected with TREM2 were subjected to cell membrane biotinylation for purification. Bottom panel in (D) shows the presence of TREM2 in the
purified product. Endogenous APP and b-tubulin were used as controls for the purification (middle and upper panels). Experiment was replicated 3 independent
times.
Source data are available online for this figure.
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framework to understand the structural features of the various
TREM molecules required for Ab interaction.
We confirmed the previously reported binding between TREM2
and APOE, although some of the details that we report regarding
binding are distinct (Atagi et al, 2015; Bailey et al, 2015; Yeh et al,
2016). Whereas other groups have reported reduced binding of
APOE with TREM2 AD variants (Atagi et al, 2015; Bailey et al,
2015; Yeh et al, 2016), we find little difference between the bind-
ing affinity between lipidated APOE and TREM2 or the AD vari-
ants. In fact, for APOE4 binding, we see slightly increased in
affinity for the AD variants compared to WT TREM2. Though
statistically significant, this is relatively small difference and unli-
kely to translate into biological differences with respect to func-
tion. Differences between our data and previous reports may be
due to technical differences. Yeh et al (2016) make claims about
binding affinity based on BLI but did not actually measure associa-
tion and dissociation constants. Yuka et al evaluated binding of
TREM2/APOE by dot blot and ELISA assays, which again do not
provide precise data on kinetics of binding, and Bailey et al
reported that TREM2 R47H reduced the affinity of TREM2 for
APOE used ELISA assay (Atagi et al, 2015; Bailey et al, 2015). In
contrast to Yuka et al, who reported a lack of interaction between
TREM1 and APOE in dot blot assay, we detect an interaction
between secreted TREM1 and APOE3 from media. (Atagi et al,
2015).
An interaction between TREM2 and Ab42 oligomers has also
recently been reported by several other groups (Zhao et al, 2018;
Zhong et al, 2018). Our data and these reports consistently show
stronger binding between TREM2 and Ab oligomers compared to
monomers (Zhao et al, 2018). In contrast to these other studies,
we do find reproducible and appreciable binding between mono-
meric Ab and TREM2, though the interaction is weaker than the
interaction with a known ligand APOE and much weaker than the
interaction with oligomeric Ab. We also observe a much higher
binding affinity between oligomeric Ab and TREM2 than what is
reported in these other studies. In our studies, this high affinity is
primarily driven by a Kdis that is the lowest measurable on the
Octet instrument. A prediction of the extremely low Kdis is that
the nearly irreversible binding of oligomeric Ab to TREM2 would
block interaction with another ligand. We tested this prediction
with APOE and find that this is indeed the case—prior incubation
of Ab oligomers with TREM2 blocked subsequent binding of
APOE to TREM2. A final and important discrepancy between
these reports is that we reproducibly do not detect differences in
affinity between various forms of Ab and TREM2 WT and the AD
variants in either the BLI studies or in ELISA assays. Notably,
although these other reports use BLI to calculate affinity of
TREM2 WT to oligomeric Ab, only solid-phase plate binding
assays are used to show differences in the affinity between Ab42
oligomers and TREM2 or the TREM2 variants (Zhao et al, 2018;
Zhong et al, 2018). Clearly, many factors ranging from binding
buffers to protein purity and also form Ab oligomers can alter
affinity measurements. It is likely that such differences may
account for the quantitative differences in binding affinity
observed in our study compare to these other studies. Additional
studies will be needed to reconcile these differences, which may
have important pathophysiologic implications. Indeed, we show
consistent effects of AD variants on both Ab internalization and
NFAT signaling both consistent with a partial loss of function.
However, our data indicate that these functional effects are not
attributable to decreased affinity for Ab under the conditions
tested. The functionality of interaction between Ab oligomers
and TREM2 showed an activation of NFAT signaling as observed
by Zhong et al (2018). This signaling activation was indirectly
confirmed by showing that Ab42 oligomers enhanced the interac-
tion between TREM2 and DAP12 and induced SYK phosphoryla-
tion, an important factor for NFAT signaling (Zhao et al, 2018).
Reports exploring TREM2 deficiency in mouse models of Ab
deposition have shown both differing effects on Ab levels during
early and late stages and in some cases no change in overall
amyloid loads (Ulrich et al, 2014; Jay et al, 2015, 2017; Wang
et al, 2015, 2016). Studies that showed effects on Ab deposition
reported changes in Ab loads were rather modest and regional
in nature (Ulrich et al, 2014; Wang et al, 2016). This suggests
that any interaction between TREM2 and Ab (or perhaps even
co-deposited APOE) in the peri-plaque region alters microglial
response to the plaque with a minimal effect on plaque clear-
ance (Jiang et al, 2014; Jay et al, 2015, 2017; Wang et al, 2015;
Yuan et al, 2016). Given this modeling data, we would suggest
that any interaction between TREM2 and Ab (or perhaps even
co-deposited APOE) in the peri-plaque region alters microglial
response to the plaque but would have minimal effect on plaque
clearance. Notably, recent data from one of our group show that
R47H TREM2 variant fails to restore microglial homing and acti-
vation around amyloid plaques in the mouse knockout back-
ground (Song et al, 2018). They also found that sTREM2-R47H
despite being present at equal levels as a common variant (CV)
of sTREM2 was not associated with plaques or neurons, whereas
the sTREM2-CV was. Another group showed that AD mice
Trem2 R47H heterozygous reduced myeloid cell responses to
amyloid deposition and reduction in proliferation and CD45
expression around plaque (Cheng-Hathaway et al, 2018).These
data present a conundrum given that we showed kinetics of
binding of the R47H and WT TREM2 to Ab are indistinguishable.
Further, they are hard to reconcile functionally with the
increased shedding of the Han Chinese TREM2 variant that is
reported to increase ectodomain shedding, but would not be
expected to alter the functionality of the ectodomain (Schlepckow
et al, 2017; Thornton et al, 2017). The overexpression of TREM2
appears protective. Previous studies showed protective functions
of TREM2 overexpression by facilitating Ab42 phagocytosis and
inhibited proinflammatory responses in cultured primary micro-
glia, reducing AD-related neuropathology in mice APPswe/
PS1dE9 and ameliorating tau pathology a tau mice model (Jiang
et al, 2014, 2016b). Our results tend in the same direction by
showing benefits of TREM2 expression like increasing Ab42
phagocytosis and activating cell signaling.
We present biochemical and cellular data that demonstrate that
TREM2 and select family members can bind to various forms of Ab
with the highest affinity interaction observed for Ab oligomers, and
we confirm an interaction between TREM2 and APOE (Atagi et al,
2015; Bailey et al, 2015; Yeh et al, 2016). Intracellular signaling
elicited following binding by Ab oligomers is attenuated by AD-asso-
ciated TREM2 variants, though the AD variants appear to bind both
Ab and lipidated APOE with similar affinity to interaction with WT
TREM2. These data link TREM2 to physical interactions with two
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key molecules in Alzheimer’s disease and provide clues that can
illuminate the clearly complex biology of TREM2 in health and
disease.
Materials and Methods
HEK293T cells were grown in DMEM supplemented with Hyclone
10% fetal bovine serum (GE, Utah, USA) and 1% penicillin/strepto-
mycin (Life Technologies, NY, USA). Cells were transiently trans-
fected with calcium phosphate. 2B4 reporter cells were maintained
in RPMI (Sigma, MO, USA) supplemented with 10% FBS, 1%
GlutaMAX (Gibco, NY, USA), 1 mM sodium pyruvate (Corning, VA.
USA), 1% penicillin/streptomycin (Gibco, NY, USA), and trans-
fected by retroviral transduction.
Antibodies
Antibodies are listed in Table 1.
cDNA constructions
pcDNA5-FRT-TO-TREM2, pcDNA5-FRT-TO-TREM2 R47H, pcDNA5-
FRT-TO-TREM2 R62H were a gift from Christian Haass (Klein-
berger et al, 2014). Soluble domains of human TREM2, TREM1,
TREML1 and mouse Trem2, Trem1, and Treml1 were cloned in
frame with human IgG Fc4 and V5 epitope in pTR2-CBA plasmid
(GeneScript, NJ, USA). TREMs cDNA constructions are listed in
Table 2.
Ab42 fibrils pull down
Ab42 fibril preparation and pull-down assay were performed as
described (Chakrabarty et al, 2015; Pinotsi et al, 2016). Conditioned
media with 5 mM EDTA or cellular lysate (RIPA SDS containing
buffer) were centrifuged at 18,000 g for 5 min at 4°C to remove insol-
uble materials. Supernatants were incubated with Ab42 fibrils for 1 h
at room temperature. Ab42 fibrils were centrifuged at 18,000 g for
5 min at 4°C to pellet the fibrils. Fibrils were washed with RIPA buffer
or PBS (for conditioned media samples) and centrifuged again. The
pelleted Ab42 fibrils were then dissolved in protein loading buffer
(31.25 mM Tris–HCl pH 7.5, 2% LDS, 10% glycerol, 1.5% b-mercap-
toethanol, and Orange G). Cell conditioned media samples or cell
lysates were also incubated with the fibril assay buffer to verify
proteins aggregations. Dissolved fibrils were heated at 95°C for 5 min
and loaded on Bis–Tris precast gels (Bio-Rad, CA, USA) and trans-
ferred on PVDF membrane for Western blotting. TREM2 was detected
with HA antibody, soluble trems-Fc-V5 were detected with V5 anti-
body, and fibrils were detected with 6E10 antibody.
Western blotting
PVDF membranes were blocked in TBS 0.5% casein a 1 h at room
temperature. Primary antibody diluted in TBS with 0.2% Tween-20
(TBS-T) was incubated on the membrane 1 h at room temperature.
The membranes were washed three times 5 min with TBS-T.
Secondary antibodies were diluted in TBS-T and incubated 1 h at
room temperature. The membranes were washed 3 times 5 min
with TBS-T and then analyzed with Odyssey infrared imaging
system (LI-COR Inc., NE, USA).
Purification of secreted soluble TREM-Fc-V5 family members
from cell conditioned media
Conditioned media from HEK293T-transfected cells was centrifuged
5 min at 800 g to clear cells and then transferred to a tube with
0.5% Triton X-100, complete protease inhibitors, and 5 mM EDTA.
Samples were incubated 2 h at room temperature with anti-human
IgG Fc-specific agarose beads (Sigma, MO, USA) and washed three
times with PBS. Purified proteins from agarose beads were washed
in PBS and eluted with 100 mM glycine pH 2.7 followed a neutral-
ization (pH~7.5) with 1 M Tris–HCl pH 8.8. Alternatively, agarose
beads were pre-blocked with 5% bovine serum albumin (Sigma,
MO, USA) 2 h at room temperature and washed with PBS before the
purification. Purified samples were verified by Western blot to con-
firm protein purification.
APOE interaction assay
HEK293T cells were co-transfected with soluble TREM2-Fc family
members and APOE3. The soluble TREM-Fc family members were
purified as described above with BSA pre-blocked agarose beads
anti-human IgG Fc specific. Agarose beads were washed with PBS
0.5% Triton and eluted with protein loading buffer. Eluates were
loaded on Bis–Tris precast gels and transferred on PVDF membrane
for Western blotting. Soluble TREM2 Fc-V5 and AD variants were
detected with V5 antibody, and APOE3 was detected with Ab947
antibody.
BioLayer interferometry
Soluble TREM2-Fc-V5 and TREM2-Fc-V5 family proteins were puri-
fied as described above with anti-human IgG Fc-specific agarose
beads. Ab42 monomers and oligomers were prepared as described
(Stine et al, 2003). Kinetic determination of TREM2/Ab42 oligomer
was initially performed on the Octet RED384 instrument (ForteBio
Table 1. List of antibodies used for Western blot and ELISA.
Antibodies Source Usage, dilution
TREM2 CTF Cell Signaling Western blot, 1/2,500
HA tag Cell Signaling Western blot, 1/2,500
V5 tag Invitrogen Western blot, 1/5,000







2.1.3 (Ab42) Todd. E. Golde ELISA (for coating),
50 lg/ml
HRP-4G8 BioLegend ELISA (for detection),
1/2,000




Invitrogen Western blot (for detection),
1/25,000
6E10 (amyloid) BioLegend Western blot, 1/1,000
10 of 13 EMBO Molecular Medicine 10: e9027 | 2018 ª 2018 The Authors
EMBO Molecular Medicine TREM2 interaction with amyloid peptide Christian B Lessard et al
Published online: October 19, 2018 
(Pall), CA, USA), using anti-human Fc-specific sensors (AHC,
ForteBio (Pall), CA, USA), PBS 0.002%, and Tween-20 as assay
buffer. Briefly, measurements were performed at 30°C and sensors
were activated in a 96-well microplate in PBS and agitated at
1,000 rpm for 10 min. Various dilutions of Ab42 or human lipidated
APOE3 and APOE4 (gift from Dr. David M. Holtzman) were loaded
in a 384-well microtiter plate.
A second BLI assay was developed for compatibility APOE
proteins utilizing Protein A sensors (ProA, ForteBio (Pall). CA,
USA). Protein A sensors were loaded to near-saturation with
soluble TREM-Fc-V5 family proteins in PBS, transferred to fresh
PBS for baseline measurement, then associated with Ab42
oligomer, human lipidated APOE3 or APOE4 ligands along a serial
dilution. The sensors were finally moved back to PBS for disasso-
ciation. Constant of association (kon), constant of dissociation
(kdis), and equilibrium constant of dissociation (KD) values were
determined by global fitting of the binding curves for each ligands
dilutions and calculated by applying a 1:1 interaction model (fit-
ting local, full) using the ForteBio Data Analysis software (CA,
USA) version 9.0.0.14.
ELISA binding assay
Soluble TREM-Fc family member proteins were purified and eluted
as previously described for the BioLayer Interferometry. Purified
samples were coated overnight at 4°C in 96-well plates (Immulon
4HBX, Thermo Scientific, NY, USA) in 100 mM NaCO3 pH 11. Plates
washed with PBS twice and then blocked 3 h at room temperature
with blocking buffer (Block Ace, Abd Serotec, Japan). Blocked
samples were incubated with Ab42 monomers, Ab42 oligomers, or
Ab42 fibrils at specified concentration for 1 h at room temperature.
Ab was detected with 4G8-HRP, and soluble TREM-Fc samples were
detected with anti-human IgG HRP to insure similar coating level of
proteins. Samples were developed with TMB substrate (KPL, Mary-
land, USA), and the reaction was stopped by adding 6.67% O-phos-
phoric acid (85%). The signal produced by HRP and TMB substrate
was quantified by measuring the absorbance at 450 nM.
Ab cellular uptake
HEK293T transfected cells from a 6-well plate were incubated 3 h
with 500 nM Ab42 monomers. Cells were washed two times with
PBS, incubated with trypsin 5 min, and centrifuged 3 min at 500 g.
Supernatant was removed, and cells were washed three times with
a large volume of PBS (10–15 ml/wash). Pelleted cells were lysed
with 100 ll SDS 2% for 5 min, and then, 200 ll of PBS was added.
Samples were sonicated and centrifuged at 18,000 g for 15 min at
4°C. Samples were diluted 1/40 in EC buffer (PBS containing
0.1 mM EDTA, 1% BSA, 0.05% CHAPS, pH 7.4, and 0.2% sodium
azide) and analyzed by Sandwich ELISAs for Ab42 as previously
described (Ran et al, 2014).
Biotinylation
Biotinylation experiments were performed to detect cell-surface
expression of TREM2 and the AD variants. Briefly, transfected
HEK293T cells were incubatedwith 2 mg/ml sulfo-NHS-biotin (Pierce)
in PBS for 30 min on ice. Cells werewashed with PBS 100 mMglycine,
washed twice with PBS and then lysed in RIPA buffer. Cell lysates
were incubated with streptavidin agarose resin (Pierce) overnight at
4°C and washed five times with RIPA buffer and then eluted with
protein loading buffer. Eluates were analyzed byWestern blot.
NFAT activation assay
Nuclear factor of activated T-cell (NFAT) activation assay was
performed with a GFP reporter as described previously (Wang et al,
2015). The 2B4 reporter cell lines transfected with TREM2-IRES-
DAP12 or TREM R47H-IRES-DAP12 were incubated with Ab42
oligomers for 12 h. NFAT signaling activation was measured by the
expression of GFP which was analyzed by flow cytometry. Reporter
activity is presented as percentage of cells that express GFP.
Statistical analysis
Statistics were performed with GraphPad Prims (CA, USA) version
7. Details on specific tests used are providing in the Figure legends.
Expanded View for this article is available online.
Table 2. List of TREMs cDNA constructs used for the experiments.
Plasmid Species Notes Epitope Usage
sTREM2-Fc Human Soluble
ectodomain
V5 Figs 1A, C, D,
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